Adoptive T-cell therapy can target and kill widespread malignant cells thereby inducing
durable clinical responses in melanoma and selected other malignances. However, many …

Background Human papillomavirus (HPV) infections and associated diseases remain a
serious burden worldwide. It is now clear that HPV serves as the etiological factor and …

Genetically engineered T cell therapy can induce remarkable tumor responses in
hematologic malignancies. However, it is not known if this type of therapy can be applied …

Despite the availability of major histocompatibility complex (MHC)-binding peptide
prediction algorithms, the development of T-cell vaccines against pathogen and tumor …

The myriad of peptides presented at the cell surface by class I and class II major
histocompatibility complex (MHC) molecules are referred to as the immunopeptidome and …

Abstract T cell receptor (TCR) T cell therapy is a promising cancer treatment modality.
However, its successful development for epithelial cancers may depend on the identification …

Abstract Purpose: The E6 and E7 oncoproteins of HPV-associated epithelial cancers are in
principle ideal immunotherapeutic targets, but evidence that T cells specific for these …

Nanotechnology-based antigen delivery has been developing as a vaccine strategy due to
its dose-sparing and prolonged antigen presentation features. In the current study, we …

T cell receptor (TCR)–engineered T cell therapy using high-affinity TCRs is a promising
treatment modality for cancer. Discovery of high-affinity TCRs especially against self …

Presentation of tumor-specific or tumor-associated peptides by HLA class I molecules to
CD8+ T cells is the foundation of epitope-centric cancer immunotherapies. While often in …